Medical Marijuana, Inc. (MJNA)

MJNA-LOGOMedical Marijuana, Inc. is comprised of a diversified portfolio of products, technology, businesses, and services exclusively focused on the production of high concentrate hemp oil products that are rich in cannabinoid (CBD). The company’s products range from proprietary and patented cannabinoid-based products to seed and stalk, or isolated high-value extracts formulated and manufactured for the nutraceutical, pharmaceutical, cosmeceutical, and food industries.

The services offered by Medical Marijuana, Inc. are extensive and varied. Such services range from medical clinic management to the capitalization of existing businesses and product leaders in the industry. The company also provides development of CBD-based health and wellness products and of medical-grade compounds.

Medical Marijuana, Inc. provides more than 85 proprietary and patent-pending delivery methods of cannabinoid that are more acceptable both medically and socially than the typical delivery methods in the industry. The company’s services also include licensing of its proprietary testing, packaging, genetics, labeling, production, tracking, and standardization methods for the medicinal herb industry.

The California-based Medical Marijuana, Inc. has an impressive portfolio of businesses that includes HempMeds PX, CanChew Gum, Canipa Holdings, Phytosphere, KannaLife Sciences, Red Dice Holdings, and Wellness Managed Services. These businesses, whether wholly or partially owned by Medical Marijuana, Inc., are integral pieces of the company’s business. The company’s featured products include Real Scientific Hemp Oil, Cibdex, Cibaderm, and Dixie Botanicals.

Founded in 2003, Medical Marijuana, Inc. is a publicly traded holding company that trades in the OTC market under the stock symbol MJNA. The company’s mission is to become the premier innovators in the hemp and cannabis industry, leveraging their team of professionals into sourcing, evaluating, and purchasing value-added products and companies while allowing them to retain their entrepreneurial spirit and integrity. Medical Marijuana, Inc. strives to create awareness within the industry, develop economically-stable and environmentally-friendly businesses while increasing shareholder value.


Yahoo! Finance: MJNA News

Latest Financial News for MJNA

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Super Academy Event and Product Launch in Amsterdam

SAN DIEGO, Sept. 19, 2019 /PRNewswire/ -- Medical Marijuana, Inc. ("the Company") (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® is hosting a Super Academy event in Amsterdam on Sept. 27-29. The event will give Kannaway®'s European Brand Ambassadors the opportunity to network with top Kannaway® Europe leaders, the Company's global executive team and fellow business owners. The Brightfield Group predicts that "impending regulatory changes" will drive Europe's CBD market from $318 million last year to $416 million in 2019, and also projects that market will surge 400% to $1.7 billion by 2025.

AXIM to Launch CBD Chewing Gum to Treat Chemotherapy Symptoms

Medical Marijuana (OTC: MJNA) announced that its major investment company AXIM Biotechnologies (OTCQB: AXIM) is making its cannabinoid-based chewing gum to treat chemotherapy-related symptoms. The chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), is being manufactured through AXIM's contract manufacturer Eurofins Amatsigroup in Belgium. It will be used in AXIM's upcoming clinical studies on cannabis as a treatment […]The post AXIM to Launch CBD Chewing Gum to Treat Chemotherapy Symptoms appeared first on Market Exclusive.

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Signs Agreement with Online Marketplace Dr. Cannabis

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Medical Marijuana, Inc. ("the Company") (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary HempMeds® Brasil, the first Anvisa-authorized company to import cannabidiol (CBD)-based medicines in the country, has signed a partnership agreement for Dr. Cannabis, an online marketplace that facilitates patient access to medical cannabis, to become the exclusive Brazilian reseller of the Company's CBD products. Since 2014, almost 10,000 authorizations have been granted to individual patients, allowing them to import medical cannabis on a case-by-case basis, each for a period of up to one year.

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies

SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Medical Marijuana, Inc . (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...

HempMeds®, Subsidiary of Medical Marijuana, Inc., Announces Presence at Natural Products Expo East

SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® will be attending and exhibiting at Natural Products Expo East in Baltimore, Maryland, on Sept. 11-14. According to a 2019 report by Natural Food Merchandiser magazine, the Natural Products Market produced over $158 million in sales in 2018 and is projected to grow by 49 percent in 2019. At the conference, HempMeds® will exhibit its well-trusted hemp-derived CBD lifestyle brands such as its Real Scientific Hemp Oil™ and Dixie Botanicals® as well as the Company's Personal Care Line of hair and skincare products, Everyday Wellness Line of functional products and brand new pet products.